Background Despite improvements in the emergency treatment of myocardial infarction (MI),
early mortality and morbidity remain high. The antiplatelet agent clopidogrel adds to the …

Background Clopidogrel and aspirin are widely used for patients with acute coronary
syndromes and those undergoing percutaneous coronary intervention (PCI). However …

Background—The risk of ischemic events is high, both early and late after acute coronary
syndromes (ACS). We examine the benefits and risks associated with the use of adding …

BACKGROUND: Many clinical trials have evaluated the benefit of long-term use of
antiplatelet drugs in reducing the risk of clinical thrombotic events. Aspirin and ticlopidine …

Background Many clinical trials have evaluated the benefit of long-term use of antiplatelet
drugs in reducing the risk of clinical thrombotic events. Aspirin and ticlopidine have been …

Background—We studied the benefits and risks of adding clopidogrel to different doses of
aspirin in the treatment of patients with acute coronary syndrome (ACS). Methods and …

Summary Abstract Clopidogrel (Plavix®, Iscover®) selectively and irreversibly inhibits
adenosine diphosphate (ADP)-induced platelet aggregation. Long-term administration of …

Background Despite current treatments, patients who have acute coronary syndromes
without ST-segment elevation have high rates of major vascular events. We evaluated the …

Antiplatelet agents are central to the treatment and prevention of cardiovascular disease.
Although aspirin is the most widely used agent, randomized trials have assessed whether …

BACKGROUND: Many clinical trials have evaluated the benefit of long-term use of
antiplatelet drugs in reducing the risk of clinical thrombotic events. Aspirin and ticlopidine …